<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7119083/results/search/drugs/results.xml">
   <result pre="inflammatory response, and antivirals, particularly the combination of lopinavir/ritonavir and" exact="ribavirin" post="have been used, but are unproven to improve outcomes"/>
   <result pre="this outbreak, the use of high-dose corticosteroids (&amp;gt; 3 g" exact="methylprednisolone" post="in the acute phase of disease) used to modulate"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7180007/results/search/drugs/results.xml">
   <result pre="of mental disorders specifically depression and anxiety (S28-S30). Agomelatine (a" exact="melatonin" post="receptor agonist) and Vilazodone (a serotonin reuptake inhibitor and"/>
   <result pre="such cases the alternative drugs (that modulate GABA signaling), including," exact="gabapentin" post="and pregabalin can be used. In case of severe"/>
   <result pre="the alternative drugs (that modulate GABA signaling), including, gabapentin and" exact="pregabalin" post="can be used. In case of severe anxiety, risperidone"/>
   <result pre="and pregabalin can be used. In case of severe anxiety," exact="risperidone" post="or quetiapine (atypical antipsychotics) should be given as an"/>
   <result pre="can be used. In case of severe anxiety, risperidone or" exact="quetiapine" post="(atypical antipsychotics) should be given as an adjunct to"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7202122/results/search/drugs/results.xml">
   <result pre="thick pleural line, b-lines &amp;amp; consolidations tend to resolve. On" exact="paracetamol" post="+ HCQ. Stopped NSAIDs. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239129472802177024;yaletung. (2020, March"/>
   <result pre="lobe much better. Left lateral appeared new focal B-lines. On" exact="paracetamol" post="+ HCQ. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239482409604861952;yaletung. (2020, March 17). Day"/>
   <result pre="&amp;amp; lateral with thick pleural line &amp;amp; focal B-lines. On" exact="paracetamol" post="+ HCQ. #mycoviddiary [Tweet]. https://twitter.com/yaletung/status/1239829327015022593. 7.HuangYWangSLiuYA preliminary study on"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7229974/results/search/drugs/results.xml">
   <result pre="fresh frozen plasma and 7 versus various pharmacologic agents including" exact="hydroxychloroquine" post="and antiviral drugs). Also our group, in collaboration with"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7265527/results/search/drugs/results.xml">
   <result pre="approved influenza antivirals were viral neuraminidase inhibitors2,3. Of these, only" exact="oseltamivir" post="(Tamiflu) can be taken orally, thereby facilitating its widespread"/>
   <result pre="the last step in the production of infectious virus. Multiple" exact="oseltamivir" post="treatments over 5 consecutive days are required to fully"/>
   <result pre="treatment10,11 (Supplementary Fig. 1). We estimated the efficacy with which" exact="oseltamivir" post="and baloxavir inhibit viral replication by fitting the model"/>
   <result pre="shows that baloxavir inhibits influenza virus replication more effectively than" exact="oseltamivir" post="(Fig. 1). Within 1 day of initiating baloxavir or"/>
   <result pre="oseltamivir (Fig. 1). Within 1 day of initiating baloxavir or" exact="oseltamivir" post="treatment, virus load decreases by an estimated 84% or"/>
   <result pre="in the clinical trial, including the initiation of baloxavir or" exact="oseltamivir" post="regimens at different times after symptom onset (Supplementary Fig."/>
   <result pre="\usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\epsilon$$\end{document} ϵ for" exact="oseltamivir" post="0.89 0.88 0.90 Initial sensitive viral load V0 (TCID50/ml)"/>
   <result pre="observations8 among patients treated with a baloxavir (427 patients), b" exact="oseltamivir" post="(377 patients), or c placebo (210 patients). Day zero"/>
   <result pre="Reduction of infectiousness by treatment with a baloxavir or b" exact="oseltamivir" post="compared with treatment with placebo. Patients were assumed to"/>
   <result pre="3a). Treatment of 30% of infected cases with baloxavir or" exact="oseltamivir" post="within 48 h after symptoms onset reduces the expected number"/>
   <result pre="predicted to reduce the overall burden of influenza more than" exact="oseltamivir" post="treatment across all treatment rates. If half of all"/>
   <result pre="rates. If half of all cases are treated, baloxavir or" exact="oseltamivir" post="are expected to reduce incidence by 58% or 39%,"/>
   <result pre="(black) or with 30% of cases receiving baloxavir (blue) or" exact="oseltamivir" post="(green) treatment. Lines indicate a moving 10-day average of"/>
   <result pre="baloxavir treatment and the increased benefit of baloxavir relative to" exact="oseltamivir" post="are greatest in the first 24 h period (Fig. 4a)."/>
   <result pre="treating the indicated percent of cases with either baloxavir or" exact="oseltamivir" post="within 48 h of symptom onset. For both graphs, the"/>
   <result pre="influenza-associated mortality and morbidity averted by scaling up baloxavir or" exact="oseltamivir" post="treatment (Fig. 4c). Specifically, we calculate the reduction in"/>
   <result pre="and mortality (38%). Clinical trial8 results indicate that baloxavir and" exact="oseltamivir" post="reduce the duration of illness by at least 23 h."/>
   <result pre="decreases with baloxavir treatment to a greater extent than with" exact="oseltamivir" post="treatment (Fig. 4c). For example, when only 20% of"/>
   <result pre="is expected to avert one DALY, whereas 18.6 courses of" exact="oseltamivir" post="treatment are needed to avert one DALY. Hence, each"/>
   <result pre="to avert one DALY. Hence, each course of baloxavir or" exact="oseltamivir" post="treatment is expected to prevent the loss of ~5"/>
   <result pre="higher mortality rates24. The relative benefits of mass treatment with" exact="oseltamivir" post="and baloxavir that we have estimated for seasonal influenza"/>
   <result pre="treatment is predicted to yield a higher herd effect than" exact="oseltamivir" post="(Supplementary Fig. 6). Seminal studies of the mitigation of"/>
   <result pre="the pandemic virus29,30. Our new estimates of time-dependent baloxavir and" exact="oseltamivir" post="efficacy against virus spread are qualitatively consistent with these"/>
   <result pre="al.Strategies for mitigating an influenza pandemicNature200644244845210.1038/nature0479516642006 30.KamalMAet al.Interdisciplinary pharmacometrics linking" exact="oseltamivir" post="pharmacology, influenza epidemiology and health economics to inform antiviral"/>
   <result pre="ClinicalTrials.govhttps://clinicaltrials.gov/ct2/show/NCT03684044 (2018). 36.KamalMAet al.A drug-disease model describing the effect of" exact="oseltamivir" post="neuraminidase inhibition on influenza virus progressionAntimicrob. Agents Chemother.2015595388539510.1128/AAC.00069-1526100715 37.MeyersLAPourbohloulBNewmanMEJSkowronskiDMBrunhamRCNetwork"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7287450/results/search/drugs/results.xml">
   <result pre="isolation of cases and contactsLancet Glob Health82020e488e49632119825 5GelerisJ.SunY.PlattJ.Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with COVID-19N Engl J Med38220202411241810.1056/NEJMoa2012410Adv Access"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7309641/results/search/drugs/results.xml">
   <result pre="a detectable viral load (470 copies/ml). The patient was treated with" exact="ribavirin" post="and steroids and experienced a mild course, not requiring"/>
   <result pre="SARS infection. In a nonrandomized study, addition of LPV/RTV to" exact="ribavirin" post="was associated with better outcome as compared with ribavirin"/>
   <result pre="to ribavirin was associated with better outcome as compared with" exact="ribavirin" post="alone [10]. Randomized control trials with LPV/RTV are currently"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7376323/results/search/drugs/results.xml">
   <result pre="the right lung (Fig. 3). Meantime, he was treated with" exact="cefuroxime" post="and traditional Chinese medicine (Lianqin oral solution and Lianhua"/>
   <result pre="at that time [7], on Day 8, we changed the" exact="cefuroxime" post="and traditional Chinese medicine to interferon atomization (5 million"/>
   <result pre="and traditional Chinese medicine to interferon atomization (5 million bid)," exact="ribavirin" post="(150 mg TID), and abidol (200 mg TID) for"/>
   <result pre="and abidol (200 mg TID) for antiviral treatment. Meanwhile, the" exact="moxifloxacin" post="(400 mg QD) was given to the patient for"/>
   <result pre="specific antiviral drugs for SARS-CoV-2. This patient was treated with" exact="ribavirin" post="and abidol, which may not inhibit the replication of"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7392634/results/search/drugs/results.xml">
   <result pre="Spain: 6.16%, France: 4.21%.102 103 Medication/treatment options Treatments being used:" exact="hydroxychloroquine" post="and chloroquine, remdesivir, azithromycin, convalescent plasma and other antivirals."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7414693/results/search/drugs/results.xml">
   <result pre="In particular the concern is the increase of illicitly manufactured" exact="fentanyl" post="used in isolation or with other drugs, such as"/>
   <result pre="in isolation or with other drugs, such as the stimulants" exact="methamphetamine" post="and cocaine, that are causing an alarming number of"/>
   <result pre="was a marked increase in deaths caused by illicitly manufactured" exact="fentanyl" post="overdoses, especially in people who used multiple illicit opioids"/>
   <result pre="people who used multiple illicit opioids and nonopioids. Illicitly manufactured" exact="fentanyl" post="was involved in approximately two-thirds of opioid deaths during"/>
   <result pre="Fentanyl or heroin combined with stimulants such as cocaine and" exact="methamphetamine" post="have led to new HIV outbreaks among PWUD throughout"/>
   <result pre="linked directly to both sharing contaminated IDU works when injecting" exact="oxymorphone" post="(Opana) as well as through condomless sexual intercourse.27 Over"/>
   <result pre="FDA-approved MOUD.33 The 3 FDA-approved MOUDs (methadone, buprenorphine, and extended-release" exact="naltrexone" post="[XR-NTX]) are successful in treating OUD through reduction in"/>
   <result pre="and overdose, and they reduce transmission of HIV and HCV33,52;" exact="buprenorphine" post="and XR-NTX also improve HIV viral suppression in PLWH,53,"/>
   <result pre="removal of the DATA 2000 X-waiver mandatory training to provide" exact="buprenorphine" post="and removal of limitations of numbers of persons with"/>
   <result pre="light of the polysubstance epidemics that include an increase in" exact="methamphetamine" post="use, that does not have effective medications to treat"/>
   <result pre="treat it. Thus, services must expand to provide clean syringes," exact="fentanyl" post="testing, and naloxone distribution. Further, federal dollars should be"/>
   <result pre="services must expand to provide clean syringes, fentanyl testing, and" exact="naloxone" post="distribution. Further, federal dollars should be released to states"/>
   <result pre="be released to states to fund provision of the syringes," exact="fentanyl" post="test strips, and naloxone, along with the staff to"/>
   <result pre="to its rootsNature5732019S10S1231511672 27PetersP.J.PontonesP.HooverK.W.HIV infection linked to injection use of" exact="oxymorphone" post="in Indiana, 2014-2015N Engl J Med375201622923927468059 28QuinonesS.Dreamland1st edition2015Bloomsbury PressNew"/>
   <result pre="abuse treatment outcomes for released HIV-infected prisoners: the impact of" exact="buprenorphine" post="treatmentJ Urban Health87201059260220177974 54SpringerS.A.Di PaolaA.AzarM.M.Extended-release naltrexone improves viral suppression"/>
   <result pre="prisoners: the impact of buprenorphine treatmentJ Urban Health87201059260220177974 54SpringerS.A.Di PaolaA.AzarM.M.Extended-release" exact="naltrexone" post="improves viral suppression among incarcerated persons living with HIV"/>
   <result pre="double-blind, placebo-controlled randomized trialJ Acquir Immune Defic Syndr782018435329373393 55SpringerS.A.QiuJ.Saber-TehraniA.S.Retention on" exact="buprenorphine" post="is associated with high levels of maximal viral suppression"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7419580/results/search/drugs/results.xml">
   <result pre="available that reference secondary infections showed that most clinicians prescribed" exact="meropenem" post="and linezolid to children with a rate of prophylactic"/>
   <result pre="reference secondary infections showed that most clinicians prescribed meropenem and" exact="linezolid" post="to children with a rate of prophylactic treatment between"/>
   <result pre="type of antibiotics used. The most commonly used antibiotics were" exact="moxifloxacin" post="(n = 452, 39.2%) and azithromycin (n = 294,"/>
   <result pre="commonly used antibiotics were moxifloxacin (n = 452, 39.2%) and" exact="azithromycin" post="(n = 294, 30.7%). Others include ceftriaxone, vancomycin, cefepime,"/>
   <result pre="maxipime, azithromycin, amoxicillin-clavulanate, cefoperazone/sulbactam, quinolone plus azithromycin, levofloxacin, moxifloxacin, and" exact="ceftriaxone" post="plus azithromycin, and most commonly azithromycin (n = 206,"/>
   <result pre="azithromycin, levofloxacin, moxifloxacin, and ceftriaxone plus azithromycin, and most commonly" exact="azithromycin" post="(n = 206, 74.6%). Of the four studies that"/>
   <result pre="was reported in three studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin," exact="moxifloxacin" post="and ceftriaxone plus azithromycin (47, 49, 51). In total,"/>
   <result pre="in three studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and" exact="ceftriaxone" post="plus azithromycin (47, 49, 51). In total, 12 patients"/>
   <result pre="studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and ceftriaxone plus" exact="azithromycin" post="(47, 49, 51). In total, 12 patients out of"/>
   <result pre="Sixty eight patients were treated with the antibiotics piperacillin-tazobactam, azithromycin," exact="ceftriaxone" post="and trimethoprim- sulfamethoxazole, levofloxacin, imipenem and other broad-spectrum antibiotics"/>
   <result pre="with the antibiotics piperacillin-tazobactam, azithromycin, ceftriaxone and trimethoprim- sulfamethoxazole, levofloxacin," exact="imipenem" post="and other broad-spectrum antibiotics (55, 56, 58, 59). The"/>
   <result pre="(96.6%) (65–67, 71, 72). The most commonly used antibiotics were" exact="vancomycin" post="(n = 317, 46.2%) and imipenem/meropenem (n = 243,"/>
   <result pre="= 243, 54.7%). Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid," exact="vancomycin" post="plus cefepime, vancomycin plus meropenem, clarithromycin, levofloxacin and dicloxacillin."/>
   <result pre="Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime," exact="vancomycin" post="plus meropenem, clarithromycin, levofloxacin and dicloxacillin. In total, 223"/>
   <result pre="cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime, vancomycin plus meropenem, clarithromycin," exact="levofloxacin" post="and dicloxacillin. In total, 223 patients of 910 (24.5%)"/>
   <result pre="one of the studies reported the use of azithromycin, vancomycin," exact="ceftriaxone" post="and cephalosporin (65). In general, all eight case studies"/>
   <result pre="study. Clin Infect Dis. (2020) 29:ciaa19910.1093/cid/ciaa199 35.GautretPLagierJCParolaPMeddebLMailheMDoudierBet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7448857/results/search/drugs/results.xml">
   <result pre="in Vero-E6 cells at noncytotoxic concentrations. The antiviral effect of" exact="gemcitabine" post="was suppressed efficiently by the cytidine nucleosides. Additionally, combination"/>
   <result pre="was suppressed efficiently by the cytidine nucleosides. Additionally, combination of" exact="gemcitabine" post="with oxysophoridine had an additive antiviral effect against SARS-CoV-2."/>
   <result pre="to cause epidemics worldwide. Different compounds, such as remdesivir and" exact="chloroquine" post="have been reported to inhibit SARS-CoV-2 replication effectively in"/>
   <result pre="lycorine and oxysophoridine against SARS-CoV-2 infection in cell culture, and" exact="chloroquine" post="was used as a positive control [1]. Vero-E6 cells"/>
   <result pre="exhibited dose-dependent inhibition of 2019-CoV replication in infected cells as" exact="chloroquine" post="(Figure 1(A)). The EC50 values of gemcitabine, lycorine, oxysophoridine"/>
   <result pre="(Figure 1(A)). The EC50 values of gemcitabine, lycorine, oxysophoridine and" exact="chloroquine" post="were 1.24, 0.31, 0.18 and 1.36 μM, respectively. To confirm"/>
   <result pre="treatment of HIV and enterovirus infection, the antiviral effect of" exact="gemcitabine" post="in combination with increased concentrations of oxysophoridine was also"/>
   <result pre="expected additive inhibitory effects were observed with the combination of" exact="gemcitabine" post="and oxysophoridine. Figure 1. The antiviral activities of gemcitabine,"/>
   <result pre="n.s. indicates no statistical differences. (E) Additive anti-SARS-CoV-2 effect of" exact="gemcitabine" post="in combination with different concentrations of oxysophoridine. The asterisks"/>
   <result pre="no statistical differences. (F) Suppression of the antiviral activity of" exact="gemcitabine" post="by cytidine. Vero-E6 cells were infected with SARS-CoV-2 and"/>
   <result pre="cells were infected with SARS-CoV-2 and simultaneously treated with 10 μM" exact="gemcitabine" post="plus different concentrations of cytidine or uridine. The asterisks"/>
   <result pre="treatment of various cancers [3]. Increasing evidence has shown that" exact="gemcitabine" post="is an effective broad spectrum antiviral agent against multiple"/>
   <result pre="of SARS-CoV-2 (1.24 μM) in our study. It is thought that" exact="gemcitabine" post="might exert its antiviral activities by targeting the salvage"/>
   <result pre="SARS-CoV-2, we added additional natural nucleosides (C and U) with" exact="gemcitabine" post="in cell culture. Similar to the previous results observed"/>
   <result pre="addition of exogenous cytidine significantly inhibited the antiviral activity of" exact="gemcitabine" post="against SARS-CoV-2 (Figure 1(F)). Our results thus indicated that"/>
   <result pre="gemcitabine against SARS-CoV-2 (Figure 1(F)). Our results thus indicated that" exact="gemcitabine" post="may inhibit SARS-CoV-2 replication through the modulation of nucleotide"/>
   <result pre="are unable to draw definitive conclusions regarding the efficacy of" exact="gemcitabine" post="against SARS-CoV-2 due to the lack of in vivo"/>
   <result pre="virus (HIV) [7]. Additionally, the mean peak plasma concentration of" exact="gemcitabine" post="observed in patients with advanced non-small cell lung cancer"/>
   <result pre="Vero-E6 cell. Altogether, these results support the therapeutic potential of" exact="gemcitabine" post="as effective antivirals with low toxicity against SARS-CoV-2. Further"/>
   <result pre="SARS-CoV-2. Further in vivo evaluation about the antiviral activity of" exact="gemcitabine" post="against SARS-CoV-2 infection is going to be carried out"/>
   <result pre="CaoR, ZhangL, YangX, LiuJ, XuM, ShiZ, HuZ, ZhongW, XiaoG.2020Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
   <result pre="Chemother58:4885-93. doi: 10.1128/AAC.03036-1424841273 5KuivanenS, BespalovMM, NandaniaJ, et al.Obatoclax, saliphenylhalamide and" exact="gemcitabine" post="inhibit Zika virus infection in vitro and differentially affect"/>
   <result pre="2017;139:117–128. doi: 10.1016/j.antiviral.2016.12.02228049006 6DenisovaOV, KakkolaL, FengL, et al.Obatoclax, saliphenylhalamide, and" exact="gemcitabine" post="inhibit influenza a virus infection. J Biol Chem. 2012;287:35324–32."/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="drugs_disease_country/PMC7467230/results/search/drugs/results.xml">
   <result pre="fentanyl, with concomitant increasing injection of stimulants including cocaine and" exact="methamphetamine" post="[1–3]. As a result, the incidence of injection drug"/>
   <result pre="and soft tissue infections, is rising [2, 4–11]. Injection of" exact="fentanyl" post="or heroin alone and in combination with stimulants have"/>
   <result pre="are 3 Food and Drug Administration-approved MOUDs—methadone, buprenorphine, and extended-release" exact="naltrexone" post="(XR-NTX). Methadone is a full opioid agonist and buprenorphine"/>
   <result pre="extended-release naltrexone (XR-NTX). Methadone is a full opioid agonist and" exact="buprenorphine" post="is a partial opioid agonist, while XR-NTX is an"/>
   <result pre="craving, overdose, and HIV and HCV transmission [14, 15]; and" exact="buprenorphine" post="and XR-NTX also improve HIV viral suppression in people"/>
   <result pre="reduced transmission [16, 17]. Of the 3 MOUDs, access to" exact="methadone" post="and buprenorphine are limited by regulations. Prescribing requires special"/>
   <result pre="[16, 17]. Of the 3 MOUDs, access to methadone and" exact="buprenorphine" post="are limited by regulations. Prescribing requires special training outside"/>
   <result pre="waiver from the Drug Enforcement Agency in the case of" exact="buprenorphine" post="or treatment in a federally certified opioid treatment program"/>
   <result pre="about 5% of the nation’s physicians have waivers to prescribe" exact="buprenorphine" post="and most substance use treatment programs do not have"/>
   <result pre="treatment programs do not have opioid treatment programs, which makes" exact="methadone" post="treatment challenging to obtain [18]. Therefore, the prevailing care"/>
   <result pre="of MOUDs, and for cotreatment of related infections. 7. Eliminate the" exact="buprenorphine" post="waiver, remove patient caps, and offer grant funding for"/>
   <result pre="the requirement for clinicians to obtain a waiver to prescribe" exact="buprenorphine" post="[24]. As outlined in this paper, urgent policy action"/>
   <result pre="infections. One innovative care model combined outpatient parenteral therapy with" exact="buprenorphine" post="treatment and showed similar clinical and drug use outcomes"/>
   <result pre="identified as a major barrier preventing some physicians from integrating" exact="buprenorphine" post="into their practice for the treatment of OUD [49]."/>
   <result pre="use disorder treatment https://www.projectshout.org In addition, a reorganization of the" exact="buprenorphine" post="prescribing system is needed. In order to increase the"/>
   <result pre="prescribe MOUD and improve patient access, we recommend eliminating the" exact="buprenorphine" post="waiver requirement, removing the patient caps, and dedicating grant"/>
   <result pre="B. reports providing waiver training courses for providers to become" exact="buprenorphine" post="prescribers through the Providers Clinical Support System. A. W."/>
   <result pre="Cochrane Database Syst Rev2011; (8):CD004145. 16.SpringerSA, QiuJ, Saber-TehraniAS, AlticeFLRetention on" exact="buprenorphine" post="is associated with high levels of maximal viral suppression"/>
   <result pre="prisoners. PLoS One2012; 7:e38335.22719814 17.SpringerSA, Di PaolaA, AzarMM, et al.Extended-release" exact="naltrexone" post="improves viral suppression among incarcerated persons living with HIV"/>
   <result pre="376:367–87.20650518 48.FanucchiLC, WalshSL, ThorntonAC, NuzzoPA, LofwallMROutpatient parenteral antimicrobial therapy plus" exact="buprenorphine" post="for opioid use disorder and severe injection-related infections [published"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
